NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis $111.89 -2.05 (-1.80%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Monopar Therapeutics Stock (NASDAQ:MNPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Monopar Therapeutics alerts:Sign Up Key Stats Today's Range$109.14▼$113.9950-Day Range$68.66▼$123.8452-Week Range$32.77▼$124.82Volume221,544 shsAverage Volume236,969 shsMarket Capitalization$750.78 millionP/E RatioN/ADividend YieldN/APrice Target$118.67Consensus RatingModerate Buy Company Overview Monopar Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies. The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development. Monopar’s lead programs employ its PRIT platform to address both hematologic malignancies and solid tumors, and the company is also exploring antibody-drug conjugate approaches to expand its immunotherapeutic offerings. Through these efforts, Monopar seeks to deliver targeted, high-potency treatments that can overcome resistance and improve patient outcomes. Founded in 2018 and headquartered in Newton, Massachusetts, Monopar Therapeutics has established research collaborations and licensing agreements to advance its proprietary technologies. The company holds global rights to its PRIT platform, which was initially developed through academic partnerships, and maintains research operations in key U.S. life-science clusters. Monopar continues to strengthen its development capabilities through strategic collaborations with academic institutions and contract research organizations. Monopar is led by a management team with extensive experience in oncology drug development, radiopharmaceutical manufacturing and clinical operations. The leadership team combines scientific expertise and industry know-how to advance the company’s pipeline and navigate regulatory pathways. Together, they are working to bring next-generation targeted therapies to patients with high-need cancers.AI Generated. May Contain Errors. Read More Monopar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreMNPR MarketRank™: Monopar Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 709th out of 919 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingMonopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Monopar Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMonopar Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Monopar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monopar Therapeutics are expected to decrease in the coming year, from ($2.94) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -51.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -51.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Monopar Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.64% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 16.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.61 News SentimentMonopar Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Monopar Therapeutics this week, compared to 4 articles on an average week.Search Interest1 people have searched for MNPR on MarketBeat in the last 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $806,766.00 in company stock.Percentage Held by Insiders9.70% of the stock of Monopar Therapeutics is held by insiders.Percentage Held by Institutions1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNPR Stock News HeadlinesInsider Selling: Monopar Therapeutics (NASDAQ:MNPR) Director Sells 3,142 Shares of StockAugust 28 at 6:51 AM | insidertrades.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of "Moderate Buy" by BrokeragesAugust 22, 2026 | americanbankingnews.comWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades near 4,500 dollars today, a 113-to-1 gap between book value and market reality. Treasury Secretary Scott Bessent has said he wants to monetize the asset side of the balance sheet. A revaluation could add more than 1 trillion dollars to the government's books overnight. Certain gold miners still trade as if gold were under 2,000 dollars, even as prices near record highs. | Golden Portfolio (Ad)MNPR FY2026 EPS Boosted by Brookline Capital MarketsAugust 22, 2026 | americanbankingnews.comMonopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026August 19, 2026 | markets.businessinsider.comMonopar Appoints Jeffrey D. Kent, M.D.August 19, 2026 | globenewswire.comMonopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'August 18, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), Achieve Life Sciences (ACHV) and OptimizeRx (OPRX)August 15, 2026 | theglobeandmail.comSee More Headlines MNPR Stock Analysis - Frequently Asked Questions How have MNPR shares performed this year? Monopar Therapeutics' stock was trading at $65.30 at the beginning of the year. Since then, MNPR stock has increased by 71.3% and is now trading at $111.89. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) issued its earnings results on Wednesday, August, 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. When did Monopar Therapeutics' stock split? Monopar Therapeutics's stock reverse split on Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Does Monopar Therapeutics have any subsidiaries? The following companies are subsidiaries of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager. Who are Monopar Therapeutics' major shareholders? Monopar Therapeutics' top institutional shareholders include Wellington Management Group LLP (2.36%), Bank of New York Mellon Corp (1.15%) and California State Teachers Retirement System (0.09%). Insiders that own company stock include Tactic Pharma Llc, Chandler Robinson, Andrew Cittadine, Raymond Anderson, Kim R Tsuchimoto, Christopher M Starr, Karthik Radhakrishnan and Quan Anh Vu. View institutional ownership trends. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Gold.com (GOLD), Tonix Pharmaceuticals (TNXP) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/12/2026Today8/29/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (21m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 MNPR's financial health is in the Green zone, according to TradeSmith. MNPR has been in this zone for over 21 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MNPR CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees10Year Founded2014Price Target and Rating Average Price Target for Monopar Therapeutics$118.67 High Price Target$133.00 Low Price Target$100.00 Potential Upside/Downside+6.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-13.08% Return on Assets-12.79% Debt Debt-to-Equity RatioN/A Current Ratio33.56 Quick Ratio33.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.50 per share Price / Book5.74Miscellaneous Outstanding Shares6,710,000Free Float6,061,000Market Cap$750.78 million OptionableNot Optionable Beta1.47 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MNPR) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredLeading AI Insider Issues Urgent Market WarningA leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBuy this stock todayMost tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...Chaikin Analytics | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
